Secondary imaging analysis of Essence-TIMI 73b (468 participants with hypertriglyceridaemia and noncalcified plaque): olezarsen vs placebo did not change noncalcified coronary plaque volume at 12 months (difference 2.98%, 95% CI -3.4 to 9.3).
RCTn = 468
Marston et al. Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study